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Regenerative treatment of peri-implantitis using bone substitutes
and membrane: a systematic review
Abstract
ABSTRACT Purpose: This systematic review aimed to assess the available literature for regenerative
treatment of peri-implantitis using bone graft substitutes and membranes. Methods: A search in
electronic databases was conducted to assess all types of clinical studies treating bone defects derived
from peri-implantitis using guided bone regeneration (GBR) techniques. Results: During the first
screening, 399 titles were identified. Finally, 17 articles reporting on 173 implants were included. The
articles mainly focused on radiographic bone fill of the defect. Qualitative measures of "bone fill" were
reported: 10.4% of the implants showed complete "bone fill," whereas 85.5% revealed incomplete
defect closure. No bone fill was shown in 4.0%. Little information (in 53.2%) was provided regarding
the probing depth before or after treatment. Data concerning the inflammatory status of soft tissues were
also scarce and only reported in three studies. A large heterogeneity concerning disinfection protocols
and regenerative materials used was found. The high percentage of low-quality studies rendered a
meta-analysis impossible. Conclusion: Complete fill of the bony defect using GBR seems not to be a
predictable outcome. The mucosal health status is left unconsidered in most studies. Well-controlled
trials are needed to determine predictable treatment protocols for the successful regenerative treatment
of peri-implantitis using GBR technique.
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Abstract 
 
AIM: This systematic review aimed to assess the available literature for regenerative treatment 
of peri-implantitis using bone graft substitutes and membranes.  
METHODS: A search in electronic databases was conducted to assess all types of clinical 
studies treating bone defects derived from peri-implantitis using GBR techniques.  
RESULTS: During the first screening, 399 titles were identified. Finally, seventeen articles 
reporting on 173 implants were included. The articles mainly focussed on radiographic bone fill 
of the defect. Qualitative measures of “bone fill” were reported: 10.4% of the implants showed 
complete “bone fill”, whereas 85.5% revealed incomplete defect closure. No bone fill was shown 
in 4.0%. Little information (in 53.2%) was provided regarding the probing depth before or after 
treatment. Data concerning the inflammatory status of soft tissues was also scarce and only 
reported in three studies. A large heterogeneity concerning disinfection protocols and 
regenerative materials used was found. The high percentage of low-quality studies rendered a 
meta-analysis impossible.  
Conclusion: Complete fill of the bony defect using GBR seems not to be a predictable outcome. 
The mucosal health status is left unconsidered in most studies. Well-controlled trials are needed 
to determine predictable treatment protocols for the successful regenerative treatment of peri-
implantitis using GBR-technique.  
 
 
 
  
1. Introduction 
During the last decades, the use of dental implants has become a routine procedure in dentistry to 
replace one or more missing teeth. Using implant survival as the indicator of successfull clinical 
outcome, a majority of clinical studies have shown very positive results for dental implants. 1 
However, limited focus has been put on peri-implant mucosal health thus far. Recent studies 
reported a rate of 8.6% - 9.7% of chronic inflammation of soft and hard tissues neighbouring 
implants after five years. 2,3 Lately, a comprehensive investigation concluded, that the peri-
implant inflammation is a common clinical finding about ten years after implantation. 4 The 
pathologic conditions termed mucositis and “peri-implantitis” are considered the major 
complication in dental implantology. 3Clinical manifestations like gingival bleeding, swelling 
and at a later state, bone loss highly resemble periodontal inflammation. Plenty of research has 
been conducted, proving that both diseases have a bacterial etiology with a similar spectrum of 
pathogens. 5-7 In analogy to periodontitis and gingivitis, peri-implantitis can be distinguished 
from mucositis by the clinical finding of attachment loss to supporting tissues, i.e. to the 
supporting bone. Thus, increased peri-implant probing depth and radiographic bone loss around 
the implant’s neck are considered the most reliable parameters proving peri-implantitis. 8,9 
Additionally, bleeding on periodontal probing (BOP), though an indicator for mucositis and not 
peri-implantitis, is a relevant parameter for the risk assessment of peri-implantitis. 10 
A broad variety of different treatment modalities have been proposed for the treatment of peri-
implantitis and there is still a lack of evidence concerning their indication and outcome. 11 At the 
turn of the millenium a systematic treatment scheme called “Cumulative Interceptive Supportive 
Therapy“ (CIST) 9 was formulated. Based on clinical and radiographical findings, a peri-implant 
lesion was categorized into a maintenance classification system, which consistently lead to a 
specific treatment recommendation. In the CIST-protocol, regenerative surgery using Guided 
Tissue Regeneration (GTR) techniques is recommended to fill bony defects caused by peri-
implantitis. Due to the fact that in peri-implantitis treatment regeneration is limited to bony 
tissue the term “Guided Bone Regeneration” (GBR) has obtained acceptance in the literature. 12  
There have numerous case reports, case series and clinical trials been published reporting on 
GBR-techniques in peri-implantitis treatment, in which a combination of both membranes and 
bone graft substitutes was used. However, there is limited evidence on success and reliability of 
that treatment protocol. The aim of the present review was to systematically evaluate the 
outcome of GBR using a bone graft substitute in combination with a membrane to treat bone 
defects derived from peri-implantitis on the basis of the parameters peri-implant probing depth 
(PPD), bleeding-on-probing (BOP) and marginal bone loss (BL).  
 
Material and methods 
 
Search method 
Using the U.S. National Library of Medicine (Medline), EMBASE and OVID a literature search 
was performed on articles published up to January 2008. The following synonyms and groups 
were included:  
(periimplant*) OR (peri-implant*)  
AND  
(membrane) OR (gtr) OR (gbr) 
AND 
(clinical)  
A manual search covered the reference lists of the included articles as well as of review articles 
concerning the topic. Furthermore the “related aticles” option on the NCBI website was used as 
data source. 
 
Screening and Selection 
In a first step, titles and abstracts of the electronic search were independently screened by two 
reviewers (PS, PRS) and assessed for possible inclusion in the review.  
- RCT studies comparing interventions using membrane and bone graft substitutes to 
control groups treated without GBR techniques. 
- Non-randomized clinical trials and case reports and series. 
- Only cases treating bone defects derived from marginal peri-implantitis were 
considered. Studies dealing with peri-apical peri-implantitis were not included due to 
its different etiology and therapeutic approaches. 
With respect to a valid comparability of the treatment modalities, only publications reporting on 
a treatment protocol including application of both membrane (resorbable and non resorbable) 
and bone substitutes were included.  
In a second step, the full texts of all possibly relevant studies, including manually retrieved 
articles, were then evaluated separately and independently by the same reviewers. Disagreement 
between the reviewers was resolved by discussion. 
From the included articles the data for the assessment parameters probing depth around implants 
(PPD), bleeding-on-probing (BOP) and bone level (BL) were extracted if given. The difference 
of these values before and after treatment and their weighted means were calculated if possible. 
For publications providing only means and standard deviations for a collective of peri-implantitis 
cases, differences of the means were calculated. In some cases, more detailed data from the 
authors of the more comprehensive studies was requested. 
 
Results  
Initially 399 titles and abstracts from the electronic search were screened and assessed for 
possible inclusion in the review. Out of these, titles that obviously did not meet the inclusion 
criteria were excluded in a first step and 62 studies remained for further analysis. Four additional 
articles were included by manual search and two by the “related links function”. These 68 
studies were then separately and independently evaluated by the reviewers. In this step, a further 
51 articles were excluded. The main reasons for exclusion were: animal studies (12) 13-24, review 
articles (10) 6,8,25-32, missing peri-implantitis situation or peri-implantitis treatment (9) 31,33-40, 
treatment with only membrane or only bone graft substitute or none of both (8) 41-48, in-vitro 
studies (6) 49-54 or for further reason (5) 4,55-58 (figure 1). 
Disagreement between the reviewers in 4.4 % of the cases was consequently resolved by 
discussion. 
From finally remaining 17 original articles, including 173 treated implant cases, the data for the 
assessment parameters bleeding-on-probing (BOP), periodontal probing depth (PPD) and bone 
level (BL) was extracted if given. 
 
Description of the studies 
No RCT studies comparing peri-implantitis treatment by using membrane and bone graft 
substitutes to a non-GBR treatment were found. 
Finally 17 clinical studies were included: 
- 3 controlled clinical trials 
- 2 cohort studies 
- 8 case series 
- 4 single case presentations (s. table 1) 
Different types of membranes (diverse synthetic membrane products, resorbable bovine or 
porcine collagene) were used in combination with different bone substitutes (DFDBA, 59-66 
DFDBA in combination with PepGen and PRP, 66 autogenous bone, 60,66-71 hydroxyl apatite, 63 
bovine xenografts 72,73 and algae-derived calciumcarbonate 74,75). Furthermore, a broad variety of 
different implant types were treated (table 5). 
Treatment strategies varied between the studies in terms of the pre- or postsurgical use of 
antibiotics and the kind of disinfection protocol used for implant surface decontamination. In 
most of the studies plastic or carbon curettes were used for mechanical debridement. Single 
studies used an ultrasonic scaler, rotating instruments, air powder or soft laser treatment. As a 
supportive maintenance program, different strategies concerning appointment frequency and 
treatment were executed (table 5). The re-evaluation periods in the various publications varied 
from five to 36 months. 
 
Periodontal probing depth 
Seven studies comprising 92 (53.2%) of the total 173 included implants provided information 
concerning the values of the PPD before and after the treatment or PPD reduction. All articles 
except one assessing more than three cases reported on mean values and standard deviations or 
confidence intervals. Only one of the studies reported on individual values for every treated 
implant 67. In the studies, both parametric and non-parametric statistical tests were used 
indicating the same skewness of the data. Consequently, values for the single implant often 
remain unknown and uncalculable, impeding any attempt of interstudy comparison or even 
meta-analysis. The authors’ request for more detailed information in case of insufficient data did 
not yield any useful additional information. In studies, where values for PPD were given, no 
outliers could be identified. Consequently, mean values instead of medians were calculated and 
used for comparison. Two studies reported on „healthy and firm mucosa“70,71 after treatment but 
were not included in the calculation of means. The weighted mean reduction of PPD for all 
implants was  3.29 mm (table 3). In most cases there was no data given for PPD after surgery, 
though in some cases it was possible to calculate it by subtracting probing depth reduction from 
the probing depth measured before treatment. This value served for estimating a mean value of 
the residual pocket depth of 3.23 mm post treatment. Search for Clinical Attachment Level 
(CAL) data provided no additional information. 
 
Bleeding on Probing 
Of the 17 included articles five studies reported on pre-treatment BOP values, but only three of 
these also reported on post-treatment data. It has to be noted, that most study designs included an 
immediate conservative treatment like rinsing of the peri-implant pockets prior to surgical 
treatment, so BOP values at baseline might differ from those immediately before intervention. 
Two studies suggested absence of BOP after intervention when „healthy and firm mucosa“ was 
found 70,71 (figure 2). 
 
Bone fill 
In all of the 17 included articles quantitative or qualitative data on the bone level around implant 
sites was given: seven studies (comprising 104 implants) reported a quantitative analysis of bone 
level values (table 1). In three studies mean values and standard deviations of bone level 
reduction were given. 68,74,75 One study reported the values for every single implant 67.  
Eighteen (10.4%) out of 173 implants investigated showed a complete fill of the intrabony 
defect. In 148 implant cases (85.5%) a gain of bone level was reported: ninety-eight implants 
(56.6%) showed incomplete bone-fill and 50 implants (28.9%) showed „bone win“ which was 
not further specified. Finally, seven implants (4.0%) failed to gain any new bone or showed bone 
loss, or the implant had to be removed (table 4).  
A weighted mean value of bone win of 2.1 mm was calculated after GBR treatment (table 2). 
The residual mean bone defect depth at the time of reevaluation was 2.6 mm. 
Twelve studies reported qualitative or semi-quantitative informations like „partial“ or not further 
specified „bone fill“ without providing any quantitative data (table 4, figure 3).  
 
 
Discussion  
 
This review aimed to assess the outcome of peri-implantitis treatment using membranes and 
bone graft substitutes. Unfortunately, there were no RCT studies comparing the results of peri-
implantitis treatment with GBR-techniques using both membrane and bone graft substitute, to an 
adequate control group, i.e. scaling or non-regenerative surgery. Consequently, studies of a 
lower level of evidence, like case presentations and proportions of patient cohorts from RCT 
studies with a different aim, were included in order to benefit from the available data in literature 
and to investigate possible differences the quality of data presentation. The risk of including 
confounding factors was estimated low as with GBR techniques the plausibility of intervention–
outcome affinity is high. Therefore, it was decided to enclose these non-controlled studies in the 
analysis.  
Furthermore, there was a lack of studies with numerous implants: The majority of the studies 
presented data of single cases or small case series. Only six studies included more than 7 
implants. These studies assessed clinical parameters like BOP and PPD more often. However, 
incomplete data presentation in these studies hampered comparability and rendered a meta-
analysis impossible.  
This study focussed on GBR techniques using both, bone graft substitute and membrane: this 
treatment modality represents the major part of published GBR cases. Hence, studies using 
solely one of both materials, were excluded in order not to further jeopardize the validity of 
comparison.   
There are a multitude of different implant systems with varying fixture design and different 
surfaces combined with a diversity of bone graft substitutes and barrier membranes. Therefore, 
comparison among the different peri-implant surgery cases is also problematic. 
Observation periods in the included studies ranged from five months to three years, and re-
examination intervals varied greatly. Thus, a comparison after the same period for all studies was 
impossible. Moreover, short observation times strongly limit the clinical relevance of the 
treatment outcome. Long-term follow-up examinations are required for a more valid assessment.  
Not surprisingly, all studies investigated radiographic bone morphology. However, less attention 
was paid to crucial clinical parameters like BOP and PPD. These parameters were rarely 
reported. This conflicts with the recommendations of the American Academy of Periodontology 
and the European Workshop on Periodontology which explicitly call for the data collection of 
BOP and PPD in the examination of peri-implantitis cases. 76,77 This finding indicates a 
shortcoming in soft tissue evaluation and is in accordance with a lately published review on peri-
implantitis therapy. 78 
Still, the etiology of marginal bone defects around implants is a topic of debate: Reasons for 
marginal peri-implant bone loss like adverse occlusal loading effects from hyper-contacts 79,80 
unfavourable healing 81 and the effect of position and adaption of the microgap 82 are common 
topics of the discussion about peri-implant bone loss. However, studies in periodontology prove 
a pivotal role of the soft tissues in the inflammation process. 
 
The authors concluded a mean probing depth reduction of 3.29 mm and a residual probing depth 
of 3.23 mm. It is thereby estimated that a peri-implant probe penetrates approximately 3 mm in a 
healthy situation 83,84 and according to the CIST protocol no further invasive intervention is 
indicated. Therefore, these results seem to suggest peri-implant health. However, it must be 
considered that the calculated PPD mean value was derived from a broad range of PPD values 
varying from study to study and even from case to case.  
There is clear evidence that peri-implantitis processes start as a peri-mucosal inflammation from 
the most external contact of implant and tissues, i.e. from the mucosal seal around the implant 
neck. 7,29,85 Analog to the transition from gingivitis to periodontitis the drawdown of attachment 
level is the crucial symptom to distinguish peri-mucositis from peri-implantitis. As early as in 
the 1980s, it was shown that the PPD differs from the histological pocket depth in periodontal 
sites. 86 In inflamed periodontal situations probes tend to penetrate deeper into the tissues 
because of the decreased tenseness of the soft tissues. The same effect, though more pronounced, 
has been shown for peri-implant situations. 87,88 This finding underlines that PPD assessment is 
an even more sensitive instrument for the detection of attachment loss in potentially inflamed 
situations. The inaccuracies of deeper probe penetration should not restrain practitioners from 
using this diagnostic tool: as inflammation fades in the course of treatment the difference 
between clinical and histological pocket depth will decrease and in the same way the accuracy of 
the parameter PPD will increase. Contrary to sporadically expressed assumptions, there is no 
evidence that careful peri-implant probing could damage the implant surface or create persistant 
injury to the tissues. 9,89 
Noteworthy, only three of 17 studies reported on BOP measurements. With regard to BOP 
assessment it has been shown in periodontal sites that absence of bleeding after probing is a 
reliable predictor for periodontal stability. 89-91 Consequently, BOP assessment is most 
reasonable for both peri-implantitis screening and evaluation of a peri-implantitis treatment.  
With regard to bone fill most of the studies provided only qualitative or semi-quantitative data 
for the amount of fill of the intrabony defect. For better comparability improved parameters for 
the defect size characterization would be helpful. For this purpose, reliable and quick methods 
have been published. 92,93 In this review, 10.4% of the included implant collective showed a 
complete and 85.5% at least a partial defect fill. This amounts to 96% of all analyzed cases 
where a bonefill of whatsoever extent was achieved by GBR technique. In this respect, GBR 
treatment can be assumed to lead to rather safe success. The interpolated 2.6 mm of residual 
bone defect after surgery should be interpreted with caution: both the reference level, i.e. implant 
benchmarks or neighbouring bone level, and the calculation might lead to inadequate 
conclusions. Anyhow, it should be kept in mind that there is no evidence for the need of either 
complete or incomplete defect fill. 
The assessment of the crestal bone level on conventional radiographs has been proven to be a 
highly specific testing method. 94 Thus, an initial peri-implant defect is not easily detected on the 
radiograph: Studies show that on conventional radiographs the sensitivity for identification of 
smaller defects, as expected for the onset peri-implant defect, is low. 94,95 Considerable 
improvements with CT and DVT technique have recently been reported. 96  
Of course, the radiographs provide no information about the nature of bone and interface. It is 
indeterminable in an augmented site with an apparently dense bone formation at the implant’s 
neck, whether osseointegration on a histological level has actually occured. 94 Putting the main 
focus on radiographic bone fill relies on a phenomenon of doubtful nature; there is still no 
evidence showing what kind of structure actually fills the bone defect. Furthermore, there is 
disagreement in research about the amount of remaining bone substitute and regenerated genuine 
bone, which can be expected depending on resorption time of the various bone graft materials. 94 
97-99 Autogenous bone, defined as the gold standard in bone augmentation, shows a volume loss 
of approximately 40% during healing time. On the other hand, synthetic bone graft substitutes 
show a high stability in volume, but remain nearly or completely unresorbed even several years 
after surgery. 100 In clinical practice, this implies that visual bone fill on the x-ray per se is not 
sufficient to claim a successful biological outcome after peri-implantitis treatment, 101 especially 
in the long-term. 
 
 
Conclusion  
Complete fill of bony defects caused by peri-implantitis using a GBR-protocol with membrane 
and bone graft substitutes does not seem to be a predictable outcome, although a partial defect 
fill can be expected.  
Published peri-implantitis literature lacks comprehensive studies with high number of cases that 
would enable a sound statistical analysis. The mucosal health status as a reliable indicator for 
peri-implant inflammation, reflected by the parameters BOP and PPD, is not reported in the 
majority of the studies. 
RCT studies comparing GBR treatment to non-invasive debridement in peri-implantitis cases are 
needed in order to provide evidence for an additional benefit of the use of bone graft substitutes 
and membranes. In these studies, assessment of quantitative values for bone loss, PPD and BOP 
would be desirable. 
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Figure 1 
Flow-chart of the screening procedure and included/excluded articles 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. 
Data distribution for different reported parameters Bleeding on Probing, Peri-implant Probing 
Depth and Bone Loss  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. 
Data extraction of the included studies reporting on differencies in Bleeding on Probing (∆BOP), 
Periodontal Probing Depth (∆PPD) and depth of the bony defect (∆BL) 
 
Author(s) Year of 
publica-
tion 
n Study 
design 
∆BOP 
(%) 
∆PPD 
(mm) 
∆BL 
 
Artzi et al.  
 
1998 2 
4 
cs 
 
n.d. n.d. 100% 
+ 
Bell et al. 
 
1994 
 
1 scp n.d. n.d. + 
Deporter & 
Todescan   
2001 1 scp n.d. n.d. 40% 
El Chaar & Jalbout 2002 2 cs n.d. n.d. + 
Haas et al.  2000 24 ct n.d. n.d. 2.00±1.90 
Khoury & 
Buchmann 
2001 20 
9 
cct 
 
n.d. 2.6±1.6 
5.4±3.0 
2.8±3.1 
1.9±3.2 
Kraut & Judy 1991 4 cs n.d. n.d. 100% 
Mellonig & Triplett   1993 10 
2 
cs n.d. n.d. 100% 
+ 
 
Mellonig et al.   
 
1995 
1 
1 
1 
cs 
 
 
n.d. 8mm 
8mm 
5-7mm 
9.0mm 
>6mm 
+ 
Petrungaro   2002 1 scp n.d. n.d. 100% 
Romanos & 
Nentwig   
2006 27 cs n.d. n.d. + 
Roos-Jansåker et al.   2007a 16 ct 68,7 4.2±1.5 2.3±1.2 
Roos-Jansåker et al.   2007b 29 cct 57,7 2.86±2.0 1.52±1.16 
(7x no bone fill) 
Schwarz et al.   2008 11 cct 36 1.5±0.6 + 
Suh et al.   2003 1 
2 
cs 
 
n.d. n.d. 100 
+ 
Tinti & Parma-
Benfenati   
2001 3 cs (reestablishment of 
healthy and firm 
mukosa) 
3.5 2.7 
 
von Arx et al.   1997 1 scp (reestablishment of 
healthy and firm 
mukosa) 
(reestablishment of 
healthy and firm 
mukosa) 
5.0 
n – number of implants    scp – single case presentation   cs – case series   ct – clinical trial   cct – controlled clinical trial  + - no 
further specified bone win      grey fields indicate: no data (n.d.) provided 
 
 
Table 2.   
Result of bone fill reported in the included studies 
 
 
Author(s) Year of publication Number of 
implants 
Mean ∆BL 
(mm) 
Haas et al. 2000 24 2 
Khoury & Buchmann 2001 9 
20 
1.9 
2.8 
Mellonig et al.  1995 1 
1 
9.0 
6.0 
Roos-Jansåker et al. 2007a 16 2.3 
Roos-Jansåker et al. 2007b 29 1.52 
Tinti & Parma-Benfenati 2001 3 2.0 
Von Arx et al. 1997 1 5.0 
Sum/mean  104 2.2 
Table 3. 
Studies reporting PPD reductions 
  
Author(s) Year of publication Number of 
implants 
Mean ∆PPD 
(mm) 
Khoury & Buchmann 2001 9 
20 
5.4 
2.6 
Mellonig et al.  1995 1 
1 
1 
8 
8 
6 
Roos-Jansåker et al. 2007a 16 4.2 
Roos-Jansåker et al. 2007b 29 2.86 
Schwarz et al 2008 11 1.5 
Tinti & Parma-Benfeanti 2001 3 3.5 
Sum  91 299,7 
Mean   3.29 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 4. 
Number of implants with different levels of bone fill 
 
 Complete 
bone fill 
Partial bone 
fill 
Bone fill (not 
further 
specified) 
No bone fill/bone 
loss/failure 
 
Total 
18 98 50  
Number of implants 
 (166)  
 
 
7 
 
 
173 
10.4 56.6 28.9  
%   (96.0)  
. 
 
4.0 
 
 
100 
 
 
 
 
 Table 5. Characteristics of the included studies 
Author Year Number/ type of 
implants 
 
Treatment 
protocol1 
Bone substitute/membrane  Systemical antibiotic therapy Reevalua-
tion 
period 
(month) 
Supportive 
maintenance 
program 
Artzi et al.  
 
1998 2/ int, omn 
4/ nd (hx) 
ultrasound 
instrumentation 
(DFDBA+agb+tcycl) / lamellar bone sheet 
(DFDBA+agb+tcycl) / ePTFE 
- 9 nd 
Bell et al. 
 
1994 1/ nd citric acid + tcycl DFDBA / ePTFE - 9 <6m 
Deporter & Todescan 
 
2001 1/ edp citric acid (DFDBA+tcycl) / CaSO4 amx 2g 1h pre 
0,5g/d for 7d post  
12 rx 
24 clin 
nd 
 
El Chaar & Jalbout 2002 2/ bv (hx) rotating 
instrumentation + 
citric acid 
DFDBA / resorbable bovine membrane amx 0,5g/d for 10d  6 7d post-op 
Haas et al. 
 
2000 24/ imz toluidine blue + 
soft laser (906nm) 
agb / ePTFE Augmentine for 5d 9,5 nd 
Khoury et al. 2001 20/ imz f2 
9/ imz f2 
0,2% CHX + citric 
acid + H2O2 
rinsing 
agb / ePTFE 
agb / resorbable porcine collagene 
div. 4w pre for 7d, post for 7d 36 implant cleaning 
1+2w and 3-6m 
post-op 
Kraut & Judy 1991 4/ nd (hx) hypertonic saline DFDBA+HA / ePTFE 650mg/dclindamycin for 7d  10 nd 
Mellonig & Triplett 1993 59/ brm (tt) - DFDBA / ePTFE broad band antibiotics in case of membrane 
exposure for 14-21d 
nd nd 
Mellonig et al. 
 
1995 3/ (tpc hc) 
 
tcycl DFDBA / ePTFE Doxycycline 0,1g/d for 14d 8/12 nd 
Petrungaro  2002 1/ nd citric acid + 
EDTA 
(DBDFA+PRP+PepGen) / resorbable bovine 
collagene 
10d pre mnz 1g/d+amx 11g/d for 4d 5 nd 
Romanos & Nentwig 2006 27/ nd  bdx / resorbable porcine collagene nd 24 nd 
Roos-Jansaker et al. 2007a 16/ brm H2O2 rinsing CaCO3 / Resorbable synthetic polymer amx 3x375mg/clindamycine 600mg + 
800mg mnz for 10d 
12 implant cleaning 
every 3m 
Roos-Jansaker  et al. 2007b 29/ brm H2O2 rinsing CaCO3 / Resorbable synthetic polymer amx 3x375mg/clindamycine 600mg + 
800mg mnz for 10d 
12 implant cleaning 
every 3m 
Schwarz  et al. 2008 11/ brm, clo,  
sla (2), tps, ksi, 
mtx (3), tsv, zld 
sterile 
physiological 
saline 
bdx / resorbable porcine collagene 
 
nd 24 every 2nd w 
during 2m post-
op, then monthly 
Suh  et al. 2003 1/ iti(ss) 
2/ iti(hc) 
mechanical 
smoothing 
agb / ePTFE amx 1,5g for 7d 6 
 
 
nd 
Tinti & Parma-
Benfenati 
2001 3/ brm air powder NaCO3      
tcycl-solution 
agb+DFDBA/ePTFE amx 2g 2h pre, 1g/d amx for 7d 21 monthly 
von Arx  et al. 1997 1/ iti(fb) chx 0.5% agb / resorbable polylactide amx/clv 1,875g/d for 7d  6 - 
1additional to instrumental debridement, full thickness flap and degranulation  tcycl – Tetracyclin solution   CHX – chlorhexidine    DFDBA – demineralized freeze-dried bone allograft   agb – autogenous bone    
ePTFE – expanded polytetrafluorethylene   HA – Hydroxile apatite  βTCP - -β-Tricalcium phophate   bdx – bovine derived xenograft    amx – amoxycilline   mnz – metronidazole  clv - clavulanate      nd – no data   
 
Implant types: (fb) – full body, (hc) – hollow cylinder. (hx) – hydrxyl-coated, (ss) – solid screw, (tpc) –  titanium plasma coated, (tt) – threated type, brm – Branemark, bv – Biovent, clo – Camlock, edp – Endpore, f2 
– Frialit 2, imz – imz, int – Integral, iti – ITI Straumann (non further specified), ksi – Bauer-screw,  mtx – spline twist Sulzer, omn – Omniloc, sla – ITI SLA-surface, tsv – Zimmer, zld – ZL-Duraplant 
 
